Show simple item record

dc.contributor.authorBrekke, Kurt R.
dc.contributor.authorDalen, Dag Morten
dc.contributor.authorStrøm, Steinar
dc.date.accessioned2013-05-03T11:31:59Z
dc.date.available2013-05-03T11:31:59Z
dc.date.issued2012
dc.identifier.issn1904-4526 (trykt utgave)
dc.identifier.urihttp://hdl.handle.net/11250/93886
dc.descriptionThis is an Open Access journal. www.norden.orgno_NO
dc.description.abstractPharmaceuticals account for almost a fifth of total health spending in OECD-countries. Both pharmaceutical innovations and the aging of the population explain the increasing importance of pharmaceuticals in health care. Due to the importance of patent protection and insurance coverage, pharmaceutical markets are subjected to economic regulation – both on the supply-side and the demand-side. In this paper, we briefly review the Nordic pharmaceutical market, before explaining the main regulatory policy measures taken by governments in these countries. Empirical research has been undertaken to investigate regulation and competition, and we provide a review of some of the findings.no_NO
dc.language.isoengno_NO
dc.publisherNordisk ministerrådno_NO
dc.subjectpharmaceutical marketsno_NO
dc.subjectpharmaceutical costsno_NO
dc.subjectreference pricingno_NO
dc.subjectprice capno_NO
dc.subjecthealth insuranceno_NO
dc.titleShould pharmaceutical costs be curbed?no_NO
dc.typeJournal articleno_NO
dc.typePeer reviewedno_NO
dc.source.pagenumber247-277no_NO
dc.source.journalNordic Economic Policy Reviewno_NO
dc.source.issue2no_NO
dc.identifier.doihttp://dx.doi.org/10.6027/TN2013-514


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record